司太立(603520.SH):與恆瑞醫藥關於碘帕醇注射液的合作進入實質性階段
格隆匯5月22日丨司太立(603520.SH)公告,浙江司太立製藥股份有限公司(以下簡稱“公司”)及全資子公司上海司太立製藥有限公司(以下簡稱“上海司太立”)於2020年5月11日與江蘇恆瑞醫藥股份有限公司(以下簡稱“恆瑞醫藥”)簽訂了藥品合作協議,協議雙方就碘海醇注射液及碘帕醇注射液的合作事項進行了約定。
上海司太立於近日收到國家藥品監督管理局頒發的碘帕醇注射液《藥品註冊批件》,標誌公司與恆瑞醫藥的合作進入實質性階段,後期恆瑞醫藥將在適當的時間對碘帕醇注射液進行商業化推廣。截至目前,公司與恆瑞醫藥合作協議涉及的另一產品碘海醇注射液尚處於受理審批階段。
由於醫藥產品具有高科技、高風險、高附加值的特點,容易受到一些不確定性因素的影響,能否順利獲得藥品註冊批件尚存在不確定性。本次合作約定了合作產品的定價機制及利潤分配,後續恆瑞醫藥將根據商業化推廣的情況向公司提供具體的採購訂單並根據合作產品的製造成本,最終確定合作產品的具體採購價格及數量,進而根據商業化推廣的實際銷售情況確定具體收益。因此,本次合作對公司業績的影響存在不確定性。敬請廣大投資者謹慎決策,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.